Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,581.00
(
1.15%
)
US TECH 100
23,524.00
(
1.04%
)
Dow Jones
46,208.47
(
1.38%
)
Brent Oil
96.79
(
-10.49%
)
Bitcoin
70,641.95
(
4.13%
)
News Focus
News Focus
Post# of 257272
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122807
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: ghmm post# 218070

Thursday, 03/29/2018 11:31:53 AM

Thursday, March 29, 2018 11:31:53 AM

Post# of 257272
UMRX IPOs 6.64M* shares @$12.00 (low end of anticipated range):

https://globenewswire.com/news-release/2018/03/29/1455160/0/en/Unum-Therapeutics-Announces-Pricing-of-Initial-Public-Offering.html

Unum Therapeutics uses its proprietary antibody-coupled T cell receptor (ACTR) technology in combination with tumor-targeting antibodies to activate the body’s own immune system to fight cancer.

The IPO went off at the low end of the anticipated range due to two belatedly disclosed deaths in the company’s clinical trial. The stock is down 4% as I’m typing.

Compare the above to the performance of FIXX, which IPOd yesterday (#msg-139639261).

*Assuming exercise of underwriter’s option.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today